PRESS RELEASE published on 04/02/2026 at 15:00, 4 months 10 days ago Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress Jaguar Health's crofelemer program targeting intestinal failure shows promising results with reductions in parenteral support for pediatric patients. Company sponsors ELITE PED-GI Congress in Abu Dhabi Jaguar Health ELITE PED-GI Congress Intestinal Failure Parenteral Support Reduction Crofelemer Program
BRIEF published on 03/24/2026 at 14:44, 4 months 19 days ago Jaguar Health Inc Receives Buy Rating from First Berlin Equity Research BUY Rating Jaguar Health Healthcare Innovation Market Potential First Berlin
BRIEF published on 03/24/2026 at 14:44, 4 months 19 days ago Jaguar Health Inc. reçoit une recommandation d'achat de la part de First Berlin Equity Research. Jaguar Health Premier Berlin Potentiel Du Marché Évaluation D'achat Innovation Dans Le Secteur De La Santé
PRESS RELEASE published on 03/24/2026 at 14:39, 4 months 19 days ago Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research initiates coverage on Northwest Biotherapeutics Inc., providing insights into the company's late-stage oncology developments including the promising DCVax-L immunotherapy for glioblastoma First Berlin Equity Research Northwest Biotherapeutics Inc. DCVax-L Immunotherapy Late-stage Oncology Developments USD 1.00 Price Target
BRIEF published on 03/18/2026 at 14:05, 4 months 25 days ago La FDA soutient la prolongation de l'essai clinique du crofélémer de Jaguar Health pour le MVID Jaguar Health Approbation De La FDA Traitement MVID Procès Crofelemer Trouble Pédiatrique
BRIEF published on 03/18/2026 at 14:05, 4 months 25 days ago FDA Supports Extension of Jaguar Health's Crofelemer Trial for MVID FDA Approval Jaguar Health Crofelemer Trial MVID Treatment Pediatric Disorder
PRESS RELEASE published on 03/18/2026 at 14:00, 4 months 25 days ago FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) Napo Pharmaceuticals plans single-blind extension phase for crofelemer trial in pediatric MVID patients, aiming to reduce parenteral support and improve clinical benefit. FDA supports protocol amendment Napo Pharmaceuticals Crofelemer Trial Pediatric MVID Parenteral Support FDA Support
BRIEF published on 03/16/2026 at 14:05, 4 months 27 days ago Magdalena Biosciences lance une étude préclinique sur la coca pour la suppression de l'appétit Jaguar Health Magdalena Biosciences Extrait De Coca Suppression De L'appétit Gestion De La Perte De Poids
BRIEF published on 03/16/2026 at 14:05, 4 months 27 days ago Magdalena Biosciences Launches Preclinical Study on Coca for Appetite Suppression Jaguar Health Magdalena Biosciences Coca Extract Appetite Suppression Weight Loss Management
PRESS RELEASE published on 03/16/2026 at 14:00, 4 months 27 days ago Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression Magdalena Biosciences initiates preclinical study on whole leaf coca extract for appetite suppression post-GLP-1 weight loss. Study conducted in Alberta, Canada Weight Loss Magdalena Biosciences Preclinical Study Appetite Suppression Whole Leaf Coca Extract
Published on 08/12/2026 at 23:30, 11 minutes ago CCL Industries Announces Record Results for 2026 Second Quarter
Published on 08/12/2026 at 23:30, 11 minutes ago Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil's Iron Quadrangle
Published on 08/12/2026 at 23:20, 21 minutes ago RJK Explorations Ltd. Announces Upsize of Previously Announced Private Placement
Published on 08/12/2026 at 23:05, 36 minutes ago Vox Royalty Reports Q2 2026 Results And Declares Quarterly Dividend
Published on 08/12/2026 at 22:01, 1 hour 40 minutes ago Fermi Names Lee McIntire as Chief Executive Officer
Published on 08/12/2026 at 21:05, 2 hours 36 minutes ago Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
Published on 08/12/2026 at 19:57, 3 hours 43 minutes ago EQS-Adhoc: Hypoport SE: Hypoport SE resolves share buyback programme with a volume of up to EUR 10 million
Published on 08/12/2026 at 19:37, 4 hours 3 minutes ago EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Published on 08/11/2026 at 17:45, 1 day 5 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 6 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 5 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 5 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026